To determine the efficacy of SAR442168 compared to placebo in delaying disability progression
To evaluate efficacy of SAR442168 compared to placebo on clinical endpoints, magnetic
resonance imaging (MRI) lesions, cognitive performance, physical function, and quality of
life To evaluate safety and tolerability of SAR442168 To evaluate population pharmacokinetics
(PK) of SAR442168 and relevant metabolites in NRSPMS and its relationship to efficacy and
safety To evaluate pharmacodynamics (PD) of SAR442168
Study duration will vary per participant in this event driven trial with a treatment duration
of approximately 24 to 48 months.
Participants completing the treatment period will be proposed to enroll in a separate long
term safety study.
If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.
Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.